XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Summary of Segment Reconciliation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development $ 36,852 $ 32,857
Total selling, general and administrative 12,482 13,043
Salaries and staff costs    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 6,903 5,930
Total selling, general and administrative 3,286 3,531
Stock-based compensation    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 1,660 1,279
Total selling, general and administrative 3,100 3,230
Clinical trials, outside services, and lab supplies    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 26,472 23,686
Outside services and professional fees    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total selling, general and administrative 4,369 4,133
Facilities and other    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 1,817 1,962
Total selling, general and administrative $ 1,727 $ 2,149